Evaluation of Sample Pooling for SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples with the Idylla SARS-CoV-2 Test.
COVID-19
Idylla test
SARS-CoV-2
pooling
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
22 12 2021
22 12 2021
Historique:
pubmed:
11
11
2021
medline:
6
1
2022
entrez:
10
11
2021
Statut:
ppublish
Résumé
Due to increased demand for testing, as well as restricted supply chain resources, testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to face many hurdles. Pooling several samples has been proposed as an alternative approach to address these issues. We investigated the feasibility of pooling nasopharyngeal swab (NPS) or saliva samples for SARS-CoV-2 testing with a commercial assay (Idylla SARS-CoV-2 test; Biocartis). We evaluated the 10-pool and 20-pool approaches for 149 subjects, with 30 positive samples and 119 negative samples. The 10-pool approach had sensitivity of 78.95% (95% confidence interval [CI], 54.43% to 93.95%) and specificity of 100% (95% CI, 71.51% to 100%), whereas the 20-pool approach had sensitivity of 55.56% (95% CI, 21.20% to 86.30%) and specificity of 100% (95% CI, 25% to 100%). No significant difference was observed between the results obtained with pooled NPS and saliva samples. Given the rapidity, full automation, and practical advantages of the Idylla SARS-CoV-2 assay, pooling of 10 samples has the potential to significantly increase testing capacity for both NPS and saliva samples, with good sensitivity.
Identifiants
pubmed: 34756076
doi: 10.1128/Spectrum.00996-21
pmc: PMC8579845
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0099621Références
Bull World Health Organ. 2020 Sep 1;98(9):590-598
pubmed: 33012859
J Clin Virol. 2021 May;138:104790
pubmed: 33770658
J Transl Med. 2019 Aug 6;17(1):252
pubmed: 31387586
ERJ Open Res. 2021 Dec 06;7(4):
pubmed: 34877351
Sci Transl Med. 2021 Apr 14;13(589):
pubmed: 33619081
Ann Transl Med. 2021 Jun;9(11):921
pubmed: 34350236
Emerg Infect Dis. 2021 Apr;27(4):
pubmed: 33755009
J Clin Virol. 2020 Oct;131:104570
pubmed: 32805524
PLoS One. 2021 Feb 26;16(2):e0247767
pubmed: 33635923
Emerg Infect Dis. 2020 Oct;26(10):2469-2472
pubmed: 32844739
Biopreserv Biobank. 2020 Dec;18(6):517-524
pubmed: 33175565
Emerg Microbes Infect. 2020 Dec;9(1):1356-1359
pubmed: 32459137
J Med Virol. 2020 Oct;92(10):2193-2199
pubmed: 32401343
Science. 2021 Jan 1;371(6524):27-28
pubmed: 33384364
N Engl J Med. 2020 Sep 24;383(13):1283-1286
pubmed: 32857487
Clin Microbiol Infect. 2020 Dec;26(12):1687.e1-1687.e5
pubmed: 32919074
J Med Virol. 2020 Nov;92(11):2306-2307
pubmed: 32369202
JAMA. 2020 May 19;323(19):1967-1969
pubmed: 32250394
N Engl J Med. 2020 Aug 6;383(6):e38
pubmed: 32502334
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
Nat Med. 2020 Sep;26(9):1405-1410
pubmed: 32678356
J Med Virol. 2021 Mar;93(3):1506-1511
pubmed: 32841429
Am J Clin Pathol. 2020 May 5;153(6):715-718
pubmed: 32304208
Kathmandu Univ Med J (KUMJ). 2020 Jul-Sept.;18(71):309-312
pubmed: 34158442
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33183494
J Clin Microbiol. 2021 Feb 18;59(3):
pubmed: 33262219